Cogent Biosciences launches $400M at-the-market equity offering via Guggenheim

Cogent Biosciences, Inc.

Filed prospectus supplement on Aug 10, 2026 to sell up to $400M of common stock under ATM sales agreement with Guggenheim Securities.
Offering uses automatic shelf registration on Form S-3ASR filed Nov 7, 2025; shares sold at market prices.
Gibson, Dunn & Crutcher issued legal opinion on the shares, filed as exhibit to this 8-K.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.